A new weekly injectable drug could transform the lives of more than eight million people living with Parkinson's disease, ...

Parkinson’s Disease is a progressive neurological disorder that will eventually lead to a late or end‑stage with severe ...

A new weekly injectable drug could transform the lives of more than eight million people living with Parkinson's disease, ...

Autism spectrum disorder is tied to an increased risk for Parkinson disease, even after adjusting for depression and antipsychotic/antidepressant use.

The FDA has updated the labeling for Kisunla™ (donanemab-azbt) to include a new recommended titration dosing schedule for adults with early symptomatic Alzheimer disease.

Sara Penuela Rodriguez (left), an interdisciplinary neuroscience doctoral student, administers infrared laser light therapy ...

One of the common motor symptoms of Parkinson’s disease (PD) is bradykinesia. Automated bradykinesia assessment is critically needed for helping neurologists achieve objective clinical diagnosis and ...

Evaluating the extent of motor impairment is an important aspect in Parkinson’s disease, where the Unified Parkinson’s Disease Rating Scale (UPDRS) plays a crucial role. The UPDRS assessment is ...

Ambroxol, long used for coughs in Europe, stabilized symptoms and brain-damage markers in Parkinson’s dementia patients over ...

Cardiovascular disease predominates as the leading health burden among middle-aged and older American adults, but progress in improving cardiovascular health remains slow. Comprehensive, ...

Most people with Parkinson’s disease (PD) experience at least one fall during the course of their disease. Several interventions designed to reduce falls have been studied. An up-to-date synthesis of ...

A clinical trial has revealed that Ambroxol, a common cough medicine in Europe, may help slow cognitive decline in people ...